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Abstract 
Oxytocin and vasopressin are potent stimulants of uterine contractions. The importance of 
these hormones, particularly oxytocin, in pregnancy and labour, has been extensively 
studied and has paved the way for many important discoveries focused on the management 
of uterine contractions in labour.   This includes development of therapies modelled on their 
structure or drug-delivery strategies targeting their receptors. This review will summarise 
our current knowledge of oxytocin and vasopressin signalling in myometrium and describe 
recent advances which have shed light on their roles in parturition, including novel roles for 
oxytocin as an inflammatory mediator and a regulator of gene transcription. How this 
information may impact the development and delivery of new oxytocin receptor-focussed 
therapies for preterm birth and dysfunctional labour will be discussed. Issues that warrant 
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further investigation and which are necessary for expanding the therapeutic potential of 
these important signalling molecules are also highlighted. 
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1. Introduction 
 
Oxytocin (OT) and arginine vasopressin (vasopressin, AVP) are two structurally similar 
neuropeptide hormones. They function via G protein-coupled receptor (GPCR)-mediated 
signal transduction and have both central and peripheral actions, with roles in many 
physiological and pathophysiological processes. In myometrium, the most noted roles for 
the OT-OT receptor (OTR) system include the initiation and stimulation of myometrial 
contractions during labour. Evidence for this comes from the significant OTR upregulation 
which is seen in both rats and humans during labour onset[1-3] (which increases myometrial 
sensitivity to OT) and that OT can be used to induce or augment labour, whilst OTR 
antagonists (OTR-As) can inhibit uterine contractions in late gestation and parturition[4].  
Whilst the main physiological roles for arginine vasopressin (AVP) in the body are the 
control of osmolarity and blood pressure, AVP is also a strong uterotonic[5]. Hence, AVP’s 
role in myometrium has also been studied. However, its role in parturition is less clear. 
Despite it being a potent inducer of contractions, circulating levels of AVP do not change 
with pregnancy or labour and there are only a few studies suggesting expression of AVP 
receptors is increased in late gestation and preterm labour[6,7].  
This review will summarise our current knowledge of signalling by these neuropeptides, 
particularly oxytocin, in myometrium and highlight recent advances in our understanding of 
their role in parturition.  Clinical considerations for their use as therapeutics to manage 
labour contractions will also be discussed well as important issues that warrant further 
investigation. 
 
2. Classical signalling by the OT-OTR system in myometrium 
The OTR is a Class 1 GPCR. As with all GPCRs, their activation leads to coupling of 
heterotrimeric G proteins, Gα, Gβ and Gγ, to stimulate a number of signalling pathways and 
regulate diverse cellular processes.  In heterologous cell systems, OTRs have been shown to 
recruit and activate Gq, Gi (Gi1 Gi2 and Gi3) and the Go (GoA, GoB) families of Gα proteins but 
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not Gs[8].   To date in myometrium, the OTR has been shown to couple to Gαq/11, Gαi and 
potentially Gα12/13, however, there is a lack of knowledge around the exact role of these and 
other Gα subunits in human myometrium. Figure 1 details the currently known mechanisms 
leading to contraction in myometrium following oxytocin stimulation. OTRs couple to Gαq/11 
proteins to activate phospholipase Cβ (PLC-β) which controls the hydrolysis of 
phosphatidylinositol-4, 5-bisphosphate (PIP2) into inositol-1, 4, 5-trisphosphate (IP3) and 
diacylglyerol (DAG).  These in turn control the mobilisation of Ca from the sarcoplasmic 
reticulum (SR) and the activation of protein kinase C (PKC) respectively. The increase in 
intracellular Ca ([Ca]i) brings about contraction via stimulation of Ca-dependent calmodulin 
and activation of myosin light chain kinase (MLCK).  MLCK phosphorylates Ser19 on the 
regulatory light chains of myosin enabling acto-myosin cross bridge cycling and myometrial 
contraction[4]. OT can also raise [Ca]i and hence contraction, through Ca entry. Candidate 
mechanisms include opening of L-type voltage-gated Ca channels[9], or store-operated Ca 
entry (SOCE)[10,11]. 
Calcium entry involving L-type Ca channels requires a change in membrane potential, but 
until recently, how OTR activation causes this depolarization was largely unknown.  Santi’s 
and England’s groups elegantly showed that OT inhibits the sodium-activated, high-
conductance, potassium leak channel, SLO2.1. This was via Gαq-protein signalling and 
activation of PKC.  Inhibition of SLO2.1 reduces outward K+ current and leads to membrane 
depolarization[12]. Voltage-dependent calcium channels are then activated, resulting in 
calcium influx. Oxytocin’s inhibition of SLO2.1 therefore provides a novel mechanism 
through which OT can induce Ca entry. 
Oxytocin may also maintain [Ca]i by inhibiting Ca extrusion mechanisms such as the plasma 
membrane Ca2+ ATPase (PMCA)[13-15]. Mechanistic data on this is limiting but a recent 
study shows that exposure of human myometrial strips to OT, induces phosphorylation of 
PMCA[16].  
Oxytocin signalling may also alter the interaction between myosin and actin independently 
of changes in [Ca]I via Ca sensitisation[17]. This occurs via activation of Rho proteins (likely 
via Gα12/13 proteins) which in turn leads to the activation of Rho kinase (ROCK) and 
subsequent phosphorylation and inhibition of MLCP[18]. Recently, the regulatory subunit of 
MLCP (PPP1R12B) was found to be phosphorylated during OT stimulation in human 
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myometrium[16]. Additionally, DAG –mediated production of PKC following OTR activation, 
can lead to inhibition of MLCP via the action of CPI-17[19]. 
Termination of OTR signalling is predominantly via G protein-independent, G protein-
coupled kinase (GRK) mechanisms. Following OTR stimulation, GRK phosphorylates the C- 
terminal tail of OTR and β-arrestin proteins are recruited to the receptor which sterically 
hinders further G-protein coupling, facilitates OTR internalization and receptor 
desensitisation[20,21].  Post-internalisation and agonist removal however, OTRs have been 
shown to efficiently recycle to the cell surface, re-sensitise and restore the full receptor 
response within 4 hours [22]. In myometrium β-arrestin recruitment is dependent on GRK6 
as GRK6 loss-of-function mice exhibit enhanced uterine contraction with an associated 
higher rate of stillbirth[23]. Thus, desensitisation of the receptor is important to prevent 
over-stimulation of the uterus in labour. β-arrestins can also act as scaffolding proteins for 
additional signalling pathways. In myometrium OT-induced β-arrestin recruitment has been 
linked to activation of MAPK and cell proliferation[24].  
 
3. Emerging roles for the OT-OTR system in parturition 
Recent studies suggest that oxytocin also acts as an inflammatory mediator, playing a 
central role in the inflammatory cascade leading to labour onset [25](Figure 2). In cultured 
myometrial and amnion cells, Kim et al., showed that OT activates mitogen-activated 
protein kinase (MAPK) and/or Nuclear factor kappa B (NFκB) pathways and this results in 
increased expression of prolabour genes such as cyclo-oxygenase 2 (COX-2), prostaglandins 
(PGs) and the pro-inflammatory cytokines and chemokines, IL-8, IL-6 and CCL5[26].  
Oxytocin also causes PG (PGE2 and PGF2α) production in other gestational tissues via 
upregulation of COX-2[27,28]. This local release of PGs, particularly PGF2α, will feedback to 
facilitate uterine contractions via similar mechanisms to OT (Figure 2). Prostaglandins also 
facilitate cervical ripening and dilation as well as fetal membrane rupture.  Oxytocin can 
therefore be considered as both a stimulator of uterine contractions and an activator of 
inflammatory pathways in gestational tissues including myometrium. It is therefore 
important that this dual role is considered when developing new treatments targeting the 
OTR in labour. 
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Oxytocin may mediate some of these changes in gene expression through regulation of 
micro RNAs (miRNAs) within the myometrium. Micro RNAs have been shown to be post-
transcriptional regulators of key gene expression pathways involved in parturition[29], 
including the OTR[30]. More recently, OT itself has been shown to affect the miRNA profile 
of human myometrium at term[31]. Gene targets for these miRNAs included NFκB, NFκB-
regulated genes such as IL-8, IL-6 and MMP9 and α-smooth muscle actin. Down-regulation 
of these miRNAs would favour a pro-inflammatory and pro-contractile phenotype and 
hence, promote labour onset. This also further supports OT as an inflammatory mediator in 
myometrium. Further work is required to define gene targets of other miRNAs in 
myometrium, as well as clarify the biological significance of these changes in relation to 
parturition. 
 
4. The AVP/AVPR system in myometrium  
Similar to OT, AVP is a nonapeptide. Its sequence differs to OT by just two amino acids 
(Figure 3A). AVP also signals through GPCRs, V1aR, V1bR and V2R, (AVPRs) which display high 
homology with the OTR. In contrast to the OT/OTR system however, much less is known 
about AVP signalling in myometrium and its role in parturition. To date, only the Va1R and 
V1bR have been found in myometrium [5,32], although some recent data suggests V2R is also 
expressed in human myometrium (S Arrowsmith et al., abstract in Acta Physiol 2016, 217 
(Suppl. 708), 3–158). Because of the high homology with OTRs, there is significant crosstalk 
between the receptor families and their ligands (Figure 3B and C). AVPRs may be important 
in mediating the response to OT (and vice versa).   
Differences in the affinity of OT and AVP for the different receptor families between species 
however, has hampered our understanding of the role of AVPRs in myometrium. For 
example in rodents, AVP-induced contractions are solely mediated by OTRs although this is 
not the same for human myometrium[33,34]. AVP’s uterotonic effect is thought to involve 
IP3-mediated store-Ca release with potential actions at both the V1aRs and the OTR[7]. 
However, the model systems and the selectivity of the peptides and antagonists used to test 
this are likely to confound data.  Deciphering the involvement and relative importance of 
AVP and AVPRs in human myometrium will require highly selective human receptor-subtype 
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agonists (e.g. see [35]) and antagonists as well as good models to test them[36].  New 
peptides displaying selectivity for the human V1aR and V1bR have been shown to augment 
human myometrial contractions indicating that the receptors are functional in myometrium 
(S Arrowsmith et al., abstract in Acta Physiol 2016, 217 (Suppl. 708), 3–158). Associations 
between OTRs and some AVPRs with potential important functional consequences have also 
been reported and are discussed later. 
 
5. Clinical considerations 
5.1. Targeting the OTR (or AVPRs) to relax or stimulate the myometrium 
Due to its prominence in myometrial contraction, the OTR has long been a major target for 
therapies aimed at modulating uterine contractions in labour. OTR antagonists represent 
the only drugs used specifically for the management of preterm labour and atosiban is the 
only currently approved OTR-A used for this purpose. Interestingly, atosiban is primarily a 
V1aR antagonist and displays a lower affinity for the OTR[37]. Which receptor/s it 
antagonises to bring about inhibition of contraction has therefore been questioned and 
atosiban’s activity at the V1aRs in other tissues such as blood vessels may inadvertently 
cause unwanted side effects.   In addition to inhibition of Gαq signalling in myometrium, 
atosiban has also been shown to activate Gαi signalling and inflammatory pathways in 
amnion[38] which is counterintuitive and undesirable for a tocolytic. Hence, understanding 
the contribution of signalling from the different G protein subunits which are coupled to 
OTR will be essential to aid the development of effective therapeutics. 
Other more-selective OTR-As include barusiban, retosiban and nolasiban which have shown 
some promise in early in vitro studies[39-41]. However, despite a >300-fold selectivity for 
the OTR, barusiban was no more effective than placebo in stopping preterm labour in 
pregnant women[42]. Retosiban, a >1400-fold selective OTR inverse agonist, showed a 
favorable efficacy and safety profile in a phase 2 proof-of-concept study for the treatment 
of spontaneous preterm labour[43]. Interestingly, data from Smith’s group suggest 
retosiban may prevent stretch-induced uterine contractions and that OTR may also act as a 
mechanosensor in which myometrial stretch increases contractions via agoinst-free 
activation of the OTR[44].   Retosiban may be suited to delaying or preventing preterm 
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labour in multiple pregnancy. Clinical trials to test this are needed. In addition to Gαq 
signalling, nolasiban, unlike atosiban, also inhibits Gαi signalling from the OTR and therefore 
may be beneficial in that it also inhibit OT’s inflammatory action in gestational tissues[45].  
Considerations for the use of oxytocins to exogenously manage dysfunctional labour and 
postpartum haemorrhage (PPH) include dosing and delivery strategies.  Oxytocin’s release 
from the pituitary is thought to be pulsatile which compensates for its relative short half-life 
(3-4 min)[46]  and the rapid desensitisation of its receptor. However trials have shown that 
pulsatile infusion of oxytocin confers no clinical benefit for induction and is not 
recommended for augmentation[47].  
To overcome the limits of endogenous OT, a number of OT analogues have been developed 
[48,49]. The newest which has been tested in clinical trials is carbetocin. It was developed to 
be a long-lasting (80-100 min half-life), potent, selective agonist of the OTR[50].  It has 
shown a favourable side-effect profile compared to OT in trials for the prevention of PPH 
and has some desirable effects including some reduced blood loss[51] but more trial data is 
needed to confirm this.   Its longer half-life however, makes it unsuitable for use in labour 
induction[52].  Interestingly, carbetocin was found to display ‘functional selectivity’ in that, 
unlike OT, it only activates the OTR/Gαq pathway. In addition, carbetocin promotes OTR 
internalisation via a novel and yet unidentified β‐arrestin‐independent pathway. It was also 
shown to negatively influence OTR recycling to the plasma membrane[53].  
 
5.2.  Drug-delivery systems 
Using a drug delivery system which targets the uterus has the potential to minimise toxicity 
from unwanted side effects in maternal and/or fetal organs and increase drug efficacy. The 
OTR is one such attractive target. So far, liposomes conjugated to antibodies against the 
extracellular domain of OTR have been used to successfully deliver tocolytics or uterotonics 
to human myometrial tissues in vitro and modify contraction. In vivo studies in pregnant 
mice also demonstrated that the liposomes predominantly localised to uterine tissues[54]. 
Others have used the OTR-A, atosiban as their targeting element to deliver indomethacin to 
the uterus[55]. Whilst no significant change on rates of induced preterm birth in mice was 
observed, they were able deliver double the concentration of indomethacin whilst 
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importantly, decreasing fetal levels. These promising approaches open new horizons for 
drug development in obstetrics that could greatly impact the management of preterm birth 
and dysfunctional labour without multi-organ side effects.  
 
5.3. Cross talk with other receptors 
In addition to receptor cross-talk by the neuropeptides (discussed above), OTRs can also 
form homodimers (and oligomers) as well as heterodimers with other GPCRs[56]. Examples 
include V1aR/OTR, V2R/OTR, β2-adrenergic receptor (β2-AR)/OTR and PG receptor/OTR. The 
relevance of these dimers is not known, but it is easy to imagine how heterodimers 
involving GPCRs which both mediate pro-contractile effects in the myometrium (e.g. V1aR, 
FP) could have functional roles in the onset of labour. Indeed, low dose PGF2α was shown to 
improve myometrial responses to OT[57]  whilst FP receptor antagonists can suppress OT-
induced myometrial contraction[58]. Similarly, OTR antagonism has recently been shown to 
affect PGF2α-induced contractions[41]. OTR and β2-AR however, have opposing roles in 
myometrium. Despite this, they have been shown to physically interact[59,60], and β2-AR 
signalling can also affect OTR signalling in myometrium[61].  Further studies are required to 
determine the biological significance of these and other potential dimers involving OTRs. 
Importantly they must be examined in native human tissues to make their interactions and 
function physiologically relevant.   
Additionally, understanding OTR dimerization and crosstalk with other receptors may also 
open up the opportunity for the development of more effective combination treatments. In 
ex vivo studies of human contractions, the potency of a number of tocolytics is significantly 
reduced in the presence of low dose oxytocin (0.5nM)[62,63]. Hence combination tocolytics 
involving OTR-As warrants further investigation.  
 
5.4. Genetic variants in the OT/OTR system  
Single nucleotide polymorphisms (SNPs) in the OTR gene have been reported in neurologic 
disorders but the relevance of OTR SNPs in parturition remains largely unknown. Studies 
suggest that genetic variants of the OTR may alter oxytocin dose requirement for labour 
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induction[64,65] and increase the risk for preterm birth[66,67]. Variants in OTR have been 
observed in both coding and non-coding regions of the receptor, including in domains 
involved in agonist binding (which results in reduced OT binding and IP3 production), and 
truncation of the receptor[64,66].  SNPs in genes related to the process of OTR 
internalisation and desensitisation (e.g. GRK6), and the enzyme responsible for degradation 
and inactivation of OT, have also been identified[65,67]. Together these data suggest that 
there could also be a genetic factor in determining maternal sensitivity to OT which needs to 
be considered. But, before these genetic differences can be translated into therapeutic 
strategies, further studies to investigate the impact of these genetic variations on 
downstream signalling and their functional consequences are needed. 
 
Interestingly mutations in OTR transmembrane residues also changes the binding of AVP at 
the OTR from partial to full agonist[68].  Hence, these residues are critical in determining 
OTR’s response to any agonist (or antagonist) modelled on the structure of OT or AVP. They 
therefore have important consequences for the design of new therapies to modulate OTR 
function. Given AVP’s uterotonic action, this also warrants further investigation. 
 
 
6. Conclusions and future directions 
The emerging roles for oxytocin in parturition are exciting, however they highlight the 
complexity of this system. As our understanding of GPCR signalling expands, so too will our 
understanding of neuropeptide signalling in the myometrium.  We have been close to 
achieving safer, more effective tocolytics and uterotonics with preferred routes of 
administration for many years but we are not quite there yet.  A lot still remains to be done 
and several important questions remain unanswered, particularly around receptor 
dimerization and whether receptor crosstalk affects function.   Determining which G 
proteins are essential for signal transduction and hence, which we should ‘turn on’ or ‘off’ 
to regulate contractions will, in turn, determine whether functional selectivity of ligands is 
an important factor for therapy. Identification of receptor SNPs which are crucial for 
receptor function should help identify patient subpopulations who are likely to benefit from 
treatment as well as inform receptor targeting and drug-delivery strategies. Other factors 
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which have not been discussed here include how receptor expression is regulated. For this 
readers are directed to an earlier review[4].   
As with all studies, the system in which we use to test our questions is important. The OT-
OTR and AVP-AVPR systems are no exception. To obtain clinically and physiologically 
relevant data, we need studies in human myometrial tissues.   Together with further 
advances in our understanding of neuropeptide signalling in myometrium, it is exciting to 
think that, we may soon be able to provide a personalized medicine approach for the 
management of labour and treatment of preterm birth. 
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Wakle-Prabagaran M, Salkoff L, England SK, et al.: Oxytocin can regulate myometrial smooth 
muscle excitability by inhibiting the Na(+) -activated K(+) channel, Slo2.1. J Physiol 2019, 
597:137-149. 
This is the first paper in a number of years to detail a mechanism of how oxytocin receptor 
activation can lead to depolarisation of the membrane. It also documents a novel K+ 
channel (SLO 2.1) in myometrium which is linked to enhanced contractility at term. 
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contractions: A phosphoproteomic approach. Biochem Biophys Res Commun 2017, 
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phosphorylated during spontaneous contractions and in response to oxytocin stimulation. 
These phosphorylation events may shed light on mechanisms responsible for altered 
contraction in response to oxytocin. Examples include (as discussed above) 
phosphorylation of PMCA and PPP1R12B, the regulatory subunit of MLCP.  
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myometrium. 
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functional cross talk between OTR and FP receptors in myometrium.  
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Figure Legends 
Figure 1. Oxytocin receptor signalling in the myometrium leading to contraction.  
Binding of oxytocin to its receptor activates Gαq/11 which activates PLC-β, which in turn 
hydrolyses PIP2 to IP3 and DAG. IP3 causes release of Ca from the sarcoplasmic reticulum 
(SR) and DAG activates PKC.  Activation of PKC leads to the inhibition of the SLO2.1 
potassium leak channel, reducing K+ efflux and depolarises the membrane. In turn, this 
opens voltage-operated (L-type) Ca channels (VOCCs) and Ca2+ enters the cell. Inhibition of 
the Ca-ATPase pump inhibits Ca exit from the cell, thus promoting elevated [Ca]i. The 
reduction in lumenal SR [Ca] is thought to trigger store-operated Ca entry (SOCE) which is a 
process whereby depletion of luminal SR Ca stores (such as following agonist mediated SR 
Ca release or inhibition of SR/ER –ATPase ‘SERCA’) is coupled to Ca entry. That OT releases 
and thereby lowers SR Ca, is thought to trigger SOCE in myometrium. SOCE will lead to 
depolarisation and trigger the opening of L-type calcium channels and is therefore is also 
likely to contribute to Ca influx during OT stimulation.  Stim and Orai and transient potential 
superfamily of protein (Trp) homologues which mediate SOCE in other cells, are expressed 
in myometrium and hence may be involved.   The combined elevation in [Ca]i  leads to 
formation of the Ca-calmodulin (Ca-CAM) complex  which then activates MLCK,  resulting in 
acto-myosin crossbridge cycling and myometrial contraction.   
In addition, DAG-activated PKC also signals for phosphorylation of CPI-17 whilst oxytocin 
binding to OTR also activates Rho-A via (Gα12/13) which in turn activates ROCK.  Both 
phosphorylated CPI-17 and ROCK inhibit MLCP leading to increased myosin phosphorylation 
and this is the proposed mechanism of Ca sensitisation in the myometrium.   
OTR: oxytocin receptor, VOCC: voltage operated Ca channel, SLO2.1 sodium-activated, high-
conductance, potassium leak channel, TRP: Transient receptor potential channel: PLC-β: 
phospholipase C-β, PIP2: phosphatidylinositol 4,5-bisphosphate, IP3: inositol 1,4,5- 
triphosphate, DAG: diacylglycerol, PKC: protein kinase type C, CPI-17: C-kinase-activated 
protein phosphatase-1 (PP1) inhibitor 17kDa, Ca-CAM: Ca-calmodulin complex, MLCK: 
myosin light-chain kinase, MLCP: myosin light chain phosphatase, ROCK: RhoA-associated 
protein kinase, SOCE: store-operated Ca entry.  
Red pathways indicate signalling pathways with direct influences on [Ca]i whilst purple lines 
indicate Ca-independent pathways to contraction including Ca sensitisation. Dotted lines 
indicate where mechanisms are not yet fully elucidated.  
Figure modified with updates from Arrowsmith and Wray 2014., J Neuroendocrinol 2014, 
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Figure 2. Oxytocin as an inflammatory signal in myometrium and other gestational tissues. 
In addition to stimulating contractions, activation of the OTR leads to the concurrent 
activation of inflammatory pathways in myometrium and other gestational tissues such as 
amnion. In myometrium this is via activation of MAPKs, ERK1/2 and p38 kinase and NFκB 
p65/p50 subunits (shown as NFκB for simplicity). In amnion cells, OT signalling (via Gαi 
coupling) leads to ERK1/2 and p38 converging on NFκB p65 homodimers. NFκB dimers 
translocate to the nucleus where they induce expression of pro-labour genes including COX-
2, PGs and inflammatory cytokines and chemokines.   
Diacylglycerol (DAG)-induced activation of PKC and MAPK signalling also stimulates an 
increase in cytoplasmic phospholipase A2 (cPLA2) and COX-2 expression in human 
myometrial and amnion cells. In turn, this further increases PG synthesis including (PGE2 and 
PGF2α). PGs can feedback to promote myometrial contractility as well as drive cervical 
ripening and dilatation.  
OTR: oxytocin receptor, PLC-β: phospholipase C-β, PIP2: phosphatidylinositol 4,5-
bisphosphate, IP3: inositol 1,4,5- triphosphate, DAG: diacylglycerol, PKC: protein kinase type 
C, cPLA2: cytoplasmic phospholipase A2, COX-2: cyclo-oxygenase 2, PGF2α: prostaglandin F2α, 
PGE2: prostaglandin E2,  FP: PGF2α receptor, NFκB: nuclear factor kappa-light-chain-enhancer 
of activated B cells, MAPK: mitogen-activated protein kinase, ERK1/2: extracellular signal–
regulated kinases, p38: p38 mitogen-activated protein kinase. 
Red pathways indicate signalling pathways which will bring about contraction in 
myometrium whilst blue lines indicate pathways leading to activation of inflammation. 
Dotted lines indicate where sequences have been shortened for simplicity. 
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Figure 3: Significant cross-talk between OTRs and AVPRs  
A) Oxytocin and Vasopressin peptides are structurally very similar. Both are nonapeptides 
(they contain 9 amino acids) with a disulphide bridge between two cysteines.  This results in 
a 6 amino acid residue ring and a 3 amino acid residue tail. They differ by just 2 residues in 
positions 3 and 8. 
B) The high structural similarity between the hormones and the high extracellular sequence 
homology between the 4 receptor subtypes (85% between OTR and V1aR) allows for 
significant crosstalk between the receptors and their ligands (depicted by arrows).  
C) The table indicates the selectivity of human oxytocin receptors (hOTR) and arginine-
vasopressin (AVP) receptors, hV1aR, hV1bR and hV2R, to AVP and OT. Values denote affinity in 
Ki (nM).  The lower the Ki, the greater affinity of that hormone for the receptor. *defined as 
selective as compared with the other receptors of that species by the selectivity criterion of 
having a two orders of magnitude lower Ki. Table modified from Manning et al., 2012 J 
Neuroendocrinol 2012, 24:609-628. 
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